Abstract
Aldose reductase (AR) is an enzyme that catalyzes the rate limiting step of the polyol pathway of glucose metabolism. Besides reducing glucose to sorbitol, it reduces a number of lipid peroxidation derived aldehydes and their glutathione conjugates. Recent studies suggest that apart from its involvement in diabetic complications, it also has a pivotal role in inflammatory diseases such as atherosclerosis, sepsis, asthma, uveitis, and ovarian cancer. Furthermore, an excess of AR is found in different human cancers, such as liver, colon, breast, and cervical cancer. AR inhibitors have undergone up to phase-III clinical trials for diabetic complications. They are also reported as safe anti-inflammatory drugs. Therefore, future use of AR inhibitors in down-regulating major multi-diseases and inflammatory pathologies such as cancer and cardiovascular diseases could relieve some of the major health concerns worldwide.
Keywords: Aldose reductase inhibitors, diabetic neuropathy, inflammatory pathologies, polyol pathway.
Current Enzyme Inhibition
Title:Aldose Reductase: A Multi-disease Target
Volume: 10 Issue: 1
Author(s): Jaiprakash N. Sangshetti, Rashmi S. Chouthe, Nikhil S. Sakle, Indrajeet Gonjari and Devanand B. Shinde
Affiliation:
Keywords: Aldose reductase inhibitors, diabetic neuropathy, inflammatory pathologies, polyol pathway.
Abstract: Aldose reductase (AR) is an enzyme that catalyzes the rate limiting step of the polyol pathway of glucose metabolism. Besides reducing glucose to sorbitol, it reduces a number of lipid peroxidation derived aldehydes and their glutathione conjugates. Recent studies suggest that apart from its involvement in diabetic complications, it also has a pivotal role in inflammatory diseases such as atherosclerosis, sepsis, asthma, uveitis, and ovarian cancer. Furthermore, an excess of AR is found in different human cancers, such as liver, colon, breast, and cervical cancer. AR inhibitors have undergone up to phase-III clinical trials for diabetic complications. They are also reported as safe anti-inflammatory drugs. Therefore, future use of AR inhibitors in down-regulating major multi-diseases and inflammatory pathologies such as cancer and cardiovascular diseases could relieve some of the major health concerns worldwide.
Export Options
About this article
Cite this article as:
Sangshetti N. Jaiprakash, Chouthe S. Rashmi, Sakle S. Nikhil, Gonjari Indrajeet and Shinde B. Devanand, Aldose Reductase: A Multi-disease Target, Current Enzyme Inhibition 2014; 10 (1) . https://dx.doi.org/10.2174/15734080113096660007
DOI https://dx.doi.org/10.2174/15734080113096660007 |
Print ISSN 1573-4080 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6662 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Identification and Characterization of the Binding Sites of P-Glycoprotein for Multidrug Resistance-Related Drugs and Modulators
Current Medicinal Chemistry - Anti-Cancer Agents 2',6'-dihydroxy-4'-methoxy Dihydrochalcone Improves the Cognitive Impairment of Alzheimer's Disease: A Structure-activity Relationship Study
Current Topics in Medicinal Chemistry Treatment of GM2 Gangliosidosis in Adult Sandhoff Mice Using an Intravenous Self-Complementary Hexosaminidase Vector
Current Gene Therapy Systemic Involvement of IgG4-related Sclerosing Disease
Current Immunology Reviews (Discontinued) Recent Advances and Approaches in Targeting Apoptosis Signaling Pathways for Anti-Cancer Therapeutics
Current Cancer Therapy Reviews P-Selectin Glycoprotein Ligand-1 as a Potential Target for Humoral Immunotherapy of Multiple Myeloma (Supplementry Material)
Current Cancer Drug Targets FDG-PET Scan in Sarcoidosis: Clinical and Imaging Indications
Current Medical Imaging The Need for Calcium Channels in Cell Proliferation
Recent Patents on Anti-Cancer Drug Discovery Editorial (Thematic Issue: Immunophilins, Protein Chemistry and Cell Biology of a Promising New Class of Drug Targets – Part II)
Current Molecular Pharmacology The Neurobiological Bases for Development of Pharmacological Treatments of Aggressive Disorders
Current Neuropharmacology Nano Drug Delivery in Treatment of Oral Cancer, A Review of the Literature
Current Drug Targets Benzothiazole Derivatives: Novel Inhibitors of Methylglyoxal Mediated Glycation of Proteins In Vitro
Medicinal Chemistry Cathepsin D as a Promising Target for the Discovery of Novel Anticancer Agents
Current Cancer Drug Targets Recent Developments in Nanoparticle Based Targeted Delivery of Chemotherapeutics
Current Bioactive Compounds Organosulphur Compounds Induce Apoptosis and Cell Cycle Arrest in Cervical Cancer Cells via Downregulation of HPV E6 and E7 Oncogenes
Anti-Cancer Agents in Medicinal Chemistry Crocetin: an Agent Derived from Saffron for Prevention and Therapy for Cancer
Current Pharmaceutical Biotechnology Challenges and Opportunities from Basic Cancer Biology for Nanomedicine for Targeted Drug Delivery
Current Cancer Drug Targets Design and Synthesis of Coumarin Derivatives as Novel PI3K Inhibitors
Anti-Cancer Agents in Medicinal Chemistry Anti-Cancer Therapy: Targeting the Mevalonate Pathway
Current Cancer Drug Targets Nanocarriers for the Effective Treatment of Cervical Cancer: Research Advancements and Patent Analysis
Recent Patents on Drug Delivery & Formulation